The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B
Shi-Long Jiang, Shi-Long Jiang, Zhi-Bin Wang, Zhi-Bin Wang et al. • Frontiers in Pharmacology
(2021)
Vemurafenib, a BRAF V600E inhibitor, provides therapeutic benefits for patients with melanoma, but the frequent emergence of drug resistance remains a challenge. An understanding of the mechanisms underlying vemurafenib resistance may gener...
DOAJ
Open Access (DOAJ)
DOI:
10.3389/fphar.2021.720619